Retatrutide RT40 40mg*10vials

Retatrutide RT40 (40mg x 10 vials) is the flagship product in the Retatrutide triple receptor agonist series, representing the highest technological iteration level of GLP-1/GIP/GCGR metabolic research peptides. With groundbreaking comprehensive molecular optimization and an ultra-high-density active structure, RT40 surpasses RT10, RT15, ​​RT20, and RT30 in target binding activity, metabolic activity modulation intensity, and experimental stability. As the most potent high-dose research-grade peptide in the current Retatrutide product line, RT40 is specifically developed for constructing ultra-limit metabolic models, ultra-high-dose efficacy comparison experiments, cutting-edge preclinical pharmacology studies, and large-scale, long-term laboratory projects, making it a core high-quality raw material for leading academic and pharmaceutical research institutions.

Product Functions and Research Value

Retatrutide RT40 possesses peak-level synergistic metabolic regulation capabilities across three pathways, enabling comprehensive and enhanced intervention in systemic metabolic disorders. Its fully activated GLP-1 and GIP dual pathways maximally optimize insulin sensitivity, effectively reverse severe insulin resistance, stabilize long-term glycemic homeostasis, and produce potent and lasting appetite suppression and satiety, providing authoritative experimental support for in-depth research into the mechanisms of advanced diabetes and abnormal glucose metabolism. The maximally enhanced GCGR pathway exponentially increases resting energy metabolism, thoroughly accelerates deep breakdown of visceral fat and systemic lipid oxidation, effectively improves refractory severe dyslipidemia, and promotes comprehensive browning remodeling of white adipose tissue. RT40 is designed for highly challenging and cutting-edge research, including refractory severe obesity, long-term multi-stage metabolic remodeling, metabolic organ damage repair, and validation of ultra-high dose-response relationships. It can generate extremely significant experimental phenotypes and ultra-high precision, highly reproducible research data, providing strong support for high-standard preclinical research and academic output.

Core Product Advantages

1. Peak Activity of RT40: As a high-end, fully upgraded product in the Retatritide series, RT40 utilizes revolutionary molecular structure optimization and saturated target binding capabilities. Its comprehensive metabolic regulatory efficacy far surpasses all lower-version RT series products, resulting in more significant experimental differences and fully meeting the stringent standards of cutting-edge scientific research.

2. Ultra-High Concentration of 40mg: The industry's highest standard single-vial specification, with a concentration four times that of traditional 10mg products, twice that of 20mg products, and 33% higher than 30mg products. It is perfectly suited for ultra-long-term large animal models, ultra-high dose gradient extreme control experiments, and large-scale multi-parallel sample testing, significantly reducing experimental errors caused by frequent dilution and solution changes.

3. Superior Anti-Degradation and Permanent Stability: Employing the latest generation of molecular anti-degradation modification technology, it exhibits excellent resistance to metabolic degradation in complex in vivo and in vitro experimental environments. It maintains saturated high bioactivity throughout the entire long-term experimental period, ensuring ultra-stable and highly consistent experimental data. 4. Pharmaceutical-grade Ultra-high Purity Standard: Utilizing a sterile vacuum freeze-drying core process, all bioactivity of the peptide molecules is completely locked in. Each batch undergoes rigorous high-performance liquid chromatography purity testing and comes with complete Certificate of Account (COA) quality certification, featuring ultra-low impurity residue, no contamination, and pharmaceutical-grade superior quality.

5. Professional Batch Standard Packaging: 10 vials per box, integrated aseptic packaging, perfectly suited for long-term strategic laboratory stockpiling, top-tier pharmaceutical preclinical core research, key university research projects, and global bulk wholesale procurement.

Ritaglutide (RT40) 40mg*10 vials. RT40 is the flagship product in the entire Retaglutide series, representing the highest technological iteration of research peptides targeting the metabolism of GLP-1/GIP/GCGR. With breakthrough molecular optimization technology and an ultra-high activity ratio, RT40 surpasses the RT10, RT15, ​​RT20, and RT30 series in target binding capacity, metabolic regulation strength, and experimental stability. It is currently the most active.